Core Insights - Nektar Therapeutics presented new data on rezpegaldesleukin, a first-in-class IL-2 pathway agonist, showing statistically significant improvements in asthma control and atopic dermatitis symptoms in patients with comorbid conditions [1][2][3] Group 1: Clinical Trial Results - The Phase 2b REZOLVE-AD trial enrolled 393 patients with moderate-to-severe atopic dermatitis, with 99 patients having a history of asthma [3][9] - Statistically significant reductions in mean ACQ-5 scores were observed at week 16 for patients with asthma, particularly in those with uncontrolled asthma, where all active doses achieved significance compared to placebo [5][6] - Rezpegaldesleukin demonstrated improvements in primary and secondary endpoints for atopic dermatitis, including EASI-75 and EASI-90, with p-values indicating strong efficacy [6][7] Group 2: Treatment Mechanism and Implications - Rezpegaldesleukin promotes regulatory T-cell (Treg) activity, which may benefit both atopic dermatitis and asthma, suggesting a broader therapeutic potential across T-cell mediated inflammatory diseases [4][3] - The treatment's unique mechanism has not been observed with other biologics currently in development, positioning rezpegaldesleukin as a differentiated option in the market [4] Group 3: Future Developments - Long-term maintenance data from the REZOLVE-AD study is expected in Q1 2026, with plans for Phase 3 studies based on the positive results from the current trial [1][9] - The FDA granted Fast Track designation for rezpegaldesleukin for both atopic dermatitis and severe alopecia areata, indicating potential for expedited development and approval [14]